Evolent Health Inc. (NYSE: EVH) has announced a remarkable achievement in the realm of oncology care, with its program successfully reducing the use of low-value oncology regimens by over 20%. This significant milestone was detailed in a press release dated April 15, 2025, and published in the Journal of Clinical Pathways.

In the complex landscape of cancer treatment, oncologists are often faced with a myriad of FDA-approved regimens. While tools like Evolent’s clinical pathways assist in identifying high-value treatment options, there has been a notable lack of resources to help flag regimens that may not provide the best outcomes for patients. These low-value regimens can lead to lower survival rates, increased side effects, and exorbitant costs without offering additional clinical benefits.

2. The Low-Value Regimen Initiative

Evolent’s program focuses on therapies spanning 10 common cancer types, which constitute approximately 1% of all treatment requests received by the company. The identification of these regimens was the result of meticulous evaluation by Evolent’s clinical experts, who analyzed existing medical literature and real-world outcomes. The findings were then reviewed and sanctioned by the Oncology Scientific Advisory Board, composed of prominent oncologists from both community settings and academic institutions nationwide.

Dr. Andrew Hertler, Evolent’s Chief Medical Officer Emeritus and Senior Advisor, emphasized the importance of this initiative, stating, "While low-value options represent a tiny percentage of cancer drugs ordered, avoiding them can have an outsized impact on both the quality and affordability of care for patients." He highlighted the pressing need to focus on therapies that provide the greatest potential for improved patient outcomes, especially considering that medications account for approximately 60% of cancer care spending among Medicare populations.

3. Campaign Implementation and Results

In collaboration with a national health plan partner, Evolent launched a comprehensive campaign in early 2023 aimed at reducing the utilization of low-value regimens across multiple markets. This campaign included:

Provider Education: The initiative featured in-person and virtual forums where Evolent oncology pharmacists presented evidence-based discussions with clinicians.

Supportive Materials: The education effort was further bolstered by white papers and informative videos.

Technology Integration: Evolent integrated its clinical decision support system to flag low-value regimens as non-preferred. If a provider attempted to order one of these therapies, they received outreach from an Evolent clinical reviewer to discuss the case specifics and explore more effective alternatives.

Moreover, Evolent instituted pay-for-performance programs that incentivized providers to choose preferred regimens while discouraging the use of low-value options. The reduction in low-value regimen use was a key performance metric monitored through specialist scorecards distributed to oncology practices and referring providers.

The results of this initiative have been striking. From February to May 2024, the utilization of low-value regimens decreased by 20.1% compared to the same four-month period in 2023, driven by a notable 15.5% drop in provider requests for these ineffective therapies.

4. Looking Ahead

Dr. Von Nguyen, Evolent’s Chief Medical Officer, expressed enthusiasm for the program's success, stating, "The low-value regimen program showcases the power of our provider engagement model to drive change." He underscored the critical role of raising awareness among providers regarding low-value regimens and the importance of a multifaceted approach that leverages technology, performance metrics, and effective incentive structures to ensure sustainable improvements.

Evolent's initiative is now active in partnership with health plans across the United States, marking a significant step toward enhancing the quality of cancer care while also addressing the financial burdens associated with low-value treatments.

5. About Evolent Health

Evolent Health specializes in improving health outcomes for individuals with complex medical conditions through innovative solutions designed to simplify and reduce the costs of healthcare. With a national client base of leading payers and providers, Evolent is consistently recognized as one of the best workplaces in healthcare. More information about Evolent and its transformative impact on healthcare delivery can be found on their website.

This recent achievement underscores Evolent Health's commitment to advancing oncology care and exemplifies the potential for significant cost savings and improved patient outcomes through strategic innovation and provider engagement.

Original press release